Attorneys for CAP Say CMS Fee Proposals Illegal

By Joseph Burns | From the Volume XX No. 12 – September 9, 2013 Issue

CEO SUMMARY: In its comments about a proposal to change the way CMS pays for clinical laboratory and pathology services, the College of American Pathologists (CAP) said that CMS is using faulty assumptions. CAP further commented that the CMS proposal to cap physician fee schedule payments…

Read More

---

Independent Labs Won’t Get Medicare PQRI Bonuses

By Robert Michel | From the Volume XV No. 11 – August 18, 2008 Issue

CEO SUMMARY: Medicare does not intend to make bonus payments this year to independent labs currently reporting quality information for breast and colon cancer cases. The federal claims payment system is unable to pay independent labs for participating in the federal physician quality repo…

Read More

---

Quest Bites: Will Pay $2 Billion for AmeriPath

By Robert Michel | From the Volume XIV No. 6 – April 23, 2007 Issue

CEO SUMMARY: From its inception in the mid-1990s as a pathology physician practice management (PPM) company, AmeriPath was a business that its investors created specifically to be sold. Now Quest Diagnostics Incorporated is stepping up to pay a princely ransom of $2 billion to make AmeriP…

Read More

---

New Lab Firm Life Cycle Demonstrated by Focus

By Robert Michel

CEO SUMMARY: When an investment group bought Focus Diagnostics, Inc. in 2000, its business objective was to increase the value of the business and sell it between year five and ten of its ownership. Thus, the announcement last Friday that Focus Diagnostics would be acquired by Quest Diagn…

Read More

---

Failure of AD Pathlabs: Structural Weakness?

By Robert Michel | From the Volume XIII No. 1 – January 16, 2006 Issue

CEO SUMMARY: AD PathLabs is the latest in a string of business disappointments. Over the past decade, a number of anatomic pathology companies have proven that they can grow rapidly—attracting substantial volumes of specimens. But these companies seem to hit a financial wall that leads …

Read More

---

New Esoteric Lab Firm Does Two Acquisitions

By Robert Michel | From the Volume XI No. 6 – April 26, 2004 Issue

CEO SUMMARY: Armed with $70 million, American Esoteric Laboratories (AEL) wants to build a national laboratory that offers a full menu of esoteric tests. It is building a primary laboratory in Dallas, which has one of the nation’s best air transport hubs. ThromboCare Laboratories and Vi…

Read More

---

“February 2, 2004 Intelligence: Late Breaking Lab News”

By Robert Michel | From the Volume XI No. 2 – February 2, 2004 Issue

Changes are afoot in the national market for anatomic pathology services. At AmeriPath, Inc., the search is on for a new CEO. Current Chairman and CEO, James C. New retired, effective February 1. The company has commenced the search for a new CEO. New had been with AmeriPath since it…

Read More

---

Transition Issues Breed Turmoil in Many AP Groups

By R. Lewis Dark | From the Volume X No. 8 – June 16, 2003 Issue

PATHOLOGY GROUP PRACTICES ACROSS THE COUNTRY have yet to solve a major problem: in private practice settings, what is the right mix of compensation and equity for individual pathologists? The question strikes to the nub of retirement expectations. During their professional careers, can pathologists …

Read More

---

Public Labs Enjoy Boom Times As Revenues & Profits Climb

By Robert Michel | From the Volume VIII No. 7 – May 21, 2001 Issue

TAKEN COLLECTIVELY, second quarter earnings reports by public lab and pathology companies send a strong message: the lab industry is in the midst of a revenue and profit boom. It’s been more than a decade since every public lab and pathology company reported strong growth in both revenues and oper…

Read More

---

National Anatomic Pathology Companies Continue to Grow

By Robert Michel | From the Volume VII No. 13 – September 11, 2000 Issue

IT’S BOOM TIME IN ONE SEGMENT of the clinical laboratory world. The national anatomic pathology companies are posting record rates of growth and profits. The sustained and strong financial performance at DIANON Systems, Inc. and IMPATH, Inc. has not gone unnoticed…

Read More

---